FDA and EMA Publish Assessment of QbD for Marketing Applications - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA and EMA Publish Assessment of QbD for Marketing Applications


FDA and the European Medicines Agency (EMA) have published a joint assessment of quality-by-design (QbD) elements of a marketing authorization application. The joint-published document answers questions on regulatory submissions for quality target product profiles, expectations for critical quality attributes, and classification of criticality for process parameters. The assessment also answers questions in regards to the application of ICH Q8 (R2).

The assessment is the result of a pilot program launched by FDA and EMA in March 2011. The pilot program allows the two agencies to share review findings throughout the review process about QbD elements of applications that were chosen for the pilot. The assessment gives the agency the opportunity to collaborate on regulatory decisions so that quality of pharmaceutical products is consistent in the US and Europe. Experts from the Japanese Pharmaceuticals Medical Device Agency observed the first parallel assessment. FDA and EMA will publish further outcomes of the pilot as more assessments are conducted.

Source: FDA.gov

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here